GlassScriptPhysician profile
Amar Garapati
NPI 1891787388
$5,276.89
in general payments reported to CMS, 2019-2025
38 companies · $916 in 2025
The $916 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $795 · 2020: $143 · 2021: $646 · 2022: $670 · 2023: $981 · 2024: $1,125 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,022.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,075.08 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $887.55 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $365.65 | 2019-2025 | Ofev |
| Regeneron Healthcare Solutions, INC. | $298.94 | 2021-2025 | Dupixent |
| Philips North America LLC | $258.89 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Takeda Pharmaceuticals U.S.A., INC. | $197.76 | 2021-2025 | Glassia |
| Grifols USA, LLC | $181.05 | 2019-2025 | Prolastin-C Liquid |
| United Therapeutics Corporation | $178.32 | 2019-2025 | Tyvaso, Tyvaso |
| Genzyme Corporation | $151.79 | 2020-2023 | |
| Insmed, INC. | $147.29 | 2021-2025 | Arikayce |
| Mallinckrodt Hospital Products INC. | $132.62 | 2022-2023 | Acthar |
| Baxter Healthcare | $126.75 | 2021-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Merck Sharp & Dohme LLC | $125.88 | 2022-2024 | Zerbaxa, Recarbrio, Dificid |
| Janssen Pharmaceuticals, INC | $124.49 | 2019 | |
| Jazz Pharmaceuticals INC. | $92.05 | 2021-2023 | Xywav |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $89.30 | 2022-2024 | Tavneos, Tezspire |
| Mylan Specialty L.P. | $84.42 | 2019-2023 | Yupelri |
| Ani Pharmaceuticals, INC. | $81.10 | 2024-2025 | Purified Cortrophin Gel |
| Novartis Pharmaceuticals Corporation | $74.79 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $65.69 | 2019-2023 | Camzyos, Eliquis |
| Ambu INC. | $60.06 | 2021-2023 | |
| Harmony Biosciences LLC | $53.04 | 2021-2023 | Wakix |
| Vapotherm INC | $50.88 | 2021-2024 | Vapotherm |
| Actelion Pharmaceuticals US, INC. | $46.51 | 2021-2025 | Uptravi, Opsumit |
| Verona Pharma, INC. | $43.46 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $38.16 | 2023-2024 | |
| Gilead Sciences, INC. | $37.92 | 2023-2024 | Veklury |
| Hikma Pharmaceuticals USA | $32.50 | 2024 | Ryaltris |
| Melinta Therapeutics, LLC | $25.80 | 2023 | Vabomere |
| Ceribell, INC. | $25.26 | 2024 | Pocket Eeg Device |
| Teva Pharmaceuticals USA, INC. | $21.53 | 2021 | |
| Shire North American Group INC | $18.70 | 2019 | |
| Chiesi USA, INC. | $15.46 | 2019 | |
| Pulmonx Corporation | $15.35 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.18 | 2019 | |
| Genentech USA, INC. | $13.82 | 2019 | |
| Pfizer INC. | $12.51 | 2021 | |
| Circassia INC. | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amar Garapati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.